Abandoned Patents Are Your Cheapest R&D Lab
How generic and 505(b)(2) developers mine expired and lapsed pharmaceutical patents for low-cost market entry The drug development world has […]
Abandoned Patents Are Your Cheapest R&D Lab Read Post »
The Evergreening Playbook: How Pharma Extends Drug Exclusivity — and What It Actually Costs
The Patent Cliff Is Real, and So Is the Industry’s Response Every pharmaceutical executive knows the feeling. A blockbuster drug
Sync Your Patent Data: How to Reconcile Orange Book Data with Court Dockets and PTAB Filings
The pharmaceutical industry manages intellectual property through three disconnected systems. The Food and Drug Administration (FDA) maintains the Orange Book
Expired and Abandoned Drug Patents: The Hidden Goldmine Everyone Ignores
Every year, dozens of pharmaceutical patents expire quietly. A few dozen more get abandoned before they even reach their full
Expired and Abandoned Drug Patents: The Hidden Goldmine Everyone Ignores Read Post »
Orange Book Data Mining for Profits Through 505(b)(2) Strategy
The pharmaceutical industry is trapped in a pincer movement. On one side, the cost of developing a new molecular entity
Orange Book Data Mining for Profits Through 505(b)(2) Strategy Read Post »
Dead Patents, Live Money: How to Turn Abandoned Drug IP into Real Revenue
Introduction: The Graveyard With a Pulse Every year, thousands of pharmaceutical patents die quietly. No press release. No analyst call.
Dead Patents, Live Money: How to Turn Abandoned Drug IP into Real Revenue Read Post »
The Complete Guide to How Long Drug Patents Last Across the Commonwealth of Independent States (CIS)
Why CIS Patent Terms Confuse Even Experienced IP Professionals When a pharmaceutical company’s legal team maps out its global IP
How Biopharma Business Development Teams Are Building 5-Year LOE Dashboards to Protect Revenue, Time Deals, and Outmaneuver the Competition
Every year, pharmaceutical executives sit in board rooms and learn that a product generating hundreds of millions of dollars in
Turn Your Drug’s Patent Clock Into a Revenue Multiplier: Lifecycle Management and the 505(b)(2) Pathway
The Hatch-Waxman Act was never designed to be a gift to branded pharmaceutical companies. Congress passed the Drug Price Competition
